Zanubrutinib and venetoclax – pro
Recent literature shows an impressive efficacy and safety profile for the zanubrutinib and venetoclax combination. It cheved a 100% response rate in the Sequioia trial as compared with bendmustine and rituximab vs zanubrutinib alone. Findings presented at the 2024 EHA Congress showed that at a median follow-up of 31.6 months (range, 0.4-50.5), patients from arm D evaluable for response (n = 65) experienced a complete response (CR) rate of 46%, a CR with incomplete count recovery (CRi) rate of 2%, a partial response (PR) rate of 51%, and a PR with lymphocytosis rate of 2%.
It is not yet indicated together. Venclexta is FDA approved with obintuzumab or rituximab, but is well-supported off-label.
Mazyar Shadman et al, Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. Journal of Clinical Oncology
Volume 43, Number 21 July 2025
Ma S, Munir T, Lasica M, et al. Combination of zanubrutinib + venetoclax for treatment-naive CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D. Presented at: 2024 EHA Congress; June 13-16, 2024; Madrid, Spain. Abstract S160